Cytokinetics (CYTK) director granted new shares and long-dated stock options

Rhea-AI Filing Summary

CYTOKINETICS INC director James M. Daly received new equity awards in the form of shares and stock options. He was granted 2,851 shares of Common Stock at no cost, increasing his direct holdings to 3,239 shares. He also received a non-qualified stock option covering 4,301 shares of Common Stock at an exercise price of $77.15 per share. This option becomes exercisable starting on June 27, 2026 and expires on May 26, 2036, reflecting routine equity-based director compensation rather than an open-market purchase.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Daly James M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (Right to Buy)	4,301	$0.00	--
Grant/Award	Common Stock	2,851	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 4,301 shares (Direct, null); Common Stock — 3,239 shares (Direct, null)

Footnotes (1)

Key Figures

Common shares granted: 2,851 shares Shares held after grant: 3,239 shares Option grant size: 4,301 shares +3 more

6 metrics

Common shares granted 2,851 shares Award of Common Stock to director on May 27, 2026

Shares held after grant 3,239 shares Director’s direct Common Stock holdings post-transaction

Option grant size 4,301 shares Non-qualified stock option covering Common Stock

Option exercise price $77.15/share Conversion or exercise price for stock option

Option vesting start June 27, 2026 Date option first becomes exercisable

Option expiration May 26, 2036 Expiration date of non-qualified stock option

Key Terms

Non-Qualified Stock Option (Right to Buy), conversion or exercise price, grant/award acquisition, derivative

4 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

conversion or exercise price financial

"conversion_or_exercise_price: "77.1500""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

derivative financial

"transaction_type: "derivative" for the stock option entry"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daly James M

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94580

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		A		2,851	A	$0	3,239	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$77.15	05/27/2026		A		4,301		06/27/2026	05/26/2036	Common Stock	4,301	$0	4,301	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Mr. Daly	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CYTK director James M. Daly report?

James M. Daly reported receiving equity awards from Cytokinetics, including new shares and stock options. He was granted 2,851 Common Stock shares and a non-qualified stock option for 4,301 shares, both awarded as compensation rather than bought in the open market.

How many CYTK shares does James M. Daly hold after this grant?

After the grant, James M. Daly directly holds 3,239 shares of Cytokinetics Common Stock. His holdings rose from the award of 2,851 new shares, which were granted at no cost as part of his director compensation package.

What are the terms of James M. Daly’s new CYTK stock options?

Daly received a non-qualified stock option for 4,301 Cytokinetics shares at an exercise price of $77.15 per share. The option becomes exercisable on June 27, 2026 and expires on May 26, 2036, providing long-term equity exposure.

Was James M. Daly’s CYTK transaction an open-market purchase or a grant?

The transactions were equity grants, not open-market purchases. Daly received 2,851 Common Stock shares and a 4,301-share stock option as awards, both recorded with code “A” for grant or award, at a reported price of $0.00 per share.

Does this CYTK Form 4 show any insider share sales by James M. Daly?

The reported transactions show only acquisitions, with no sales. Daly received 2,851 Common Stock shares and a 4,301-share stock option as grants, and the transaction summary lists two acquisitions and zero dispositions or sales in this filing.